Literature DB >> 24605544

[16S rRNA gene sequence analysis for bacterial identification in the clinical laboratory].

Takehisa Matsumoto1, Mitsutoshi Sugano.   

Abstract

The traditional identification of bacteria on the basis of phenotypic characteristics is generally not as accurate as identification based on genotypic methods. For many years, sequencing of the 16S ribosomal RNA (rRNA) gene has served as an important tool for determining phylogenetic relationships between bacteria. The features of this molecular target that make it a useful phylogenetic tool also make it useful for bacterial detection and identification in the clinical laboratory. 16S rRNA gene sequence analysis can better identify poorly described, rarely isolated, or phenotypically aberrant strains, and can lead to the recognition of novel pathogens and noncultured bacteria. In clinical microbiology, molecular identification based on 16S rDNA sequencing is applied fundamentally to bacteria whose identification by means of other types of techniques is impossible or difficult. However, there are some cases in which 16S rRNA gene sequence analysis can not differentiate closely related bacteria such as Shigella spp. and Escherichia coli at the species level. Thus, it is important to understand the advantages and disadvantages of 16S rRNA gene sequence analysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24605544

Source DB:  PubMed          Journal:  Rinsho Byori        ISSN: 0047-1860


  2 in total

1.  Concurrent gut transcriptome and microbiota profiling following chronic ethanol consumption in nonhuman primates.

Authors:  Tasha Barr; Suhas Sureshchandra; Paul Ruegger; Jingfei Zhang; Wenxiu Ma; James Borneman; Kathleen Grant; Ilhem Messaoudi
Journal:  Gut Microbes       Date:  2018-04-27

2.  Production, characterization and bioinformatics analysis of L-asparaginase from a new Stenotrophomonas maltophilia EMCC2297 soil isolate.

Authors:  Nada A Abdelrazek; Walid F Elkhatib; Marwa M Raafat; Mohammad M Aboulwafa
Journal:  AMB Express       Date:  2020-04-15       Impact factor: 3.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.